- Home
- IMCC vs BFRI Comparison
IMCC vs BFRI Comparison
Compare IMCC & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- BFRI
- Stock Information
- Founded
- IMCC 1980
- BFRI 1997
- Country
- IMCC Israel
- BFRI United States
- Employees
- IMCC N/A
- BFRI N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- BFRI Health Care
- Exchange
- IMCC Nasdaq
- BFRI Nasdaq
- Market Cap
- IMCC 7.5M
- BFRI 6.2M
- IPO Year
- IMCC N/A
- BFRI 2021
- Fundamental
- Price
- IMCC $2.16
- BFRI $1.11
- Analyst Decision
- IMCC
- BFRI Strong Buy
- Analyst Count
- IMCC 0
- BFRI 1
- Target Price
- IMCC N/A
- BFRI $7.00
- AVG Volume (30 Days)
- IMCC 11.3K
- BFRI 158.3K
- Earning Date
- IMCC 03-27-2025
- BFRI 03-14-2025
- Dividend Yield
- IMCC N/A
- BFRI N/A
- EPS Growth
- IMCC N/A
- BFRI N/A
- EPS
- IMCC N/A
- BFRI N/A
- Revenue
- IMCC $38,042,859.00
- BFRI $35,358,000.00
- Revenue This Year
- IMCC $22.59
- BFRI $17.69
- Revenue Next Year
- IMCC $32.86
- BFRI $19.71
- P/E Ratio
- IMCC N/A
- BFRI N/A
- Revenue Growth
- IMCC N/A
- BFRI 5.17
- 52 Week Low
- IMCC $1.61
- BFRI $0.65
- 52 Week High
- IMCC $8.10
- BFRI $2.43
- Technical
- Relative Strength Index (RSI)
- IMCC 44.61
- BFRI 49.87
- Support Level
- IMCC $2.11
- BFRI $1.06
- Resistance Level
- IMCC $2.33
- BFRI $1.16
- Average True Range (ATR)
- IMCC 0.16
- BFRI 0.07
- MACD
- IMCC 0.00
- BFRI -0.00
- Stochastic Oscillator
- IMCC 20.00
- BFRI 55.00
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.